Rheumatoid Arthritis Clinical Trials in Philadelphia

Showing 2301-2320 of 3,347 trials

Communication to Improve Shared Decision-Making in ADHD

NCT02716324

The purpose of this study was to explore whether using an online patient portal plus a Care Manager is more effective than using an online portal alone in managing care for children with ADHD. Doctors at The Children's Hospital of Philadelphia currently use the online patient portal to help gather information from parents and teachers on ADHD symptoms, treatment, and medication side effects. The Care Manager is a person who meets with participants during the study to discuss their child's ADHD care. The Care Manager communicates with the child's doctor and teacher to communicate a parent's goals and preferences for their child's ADHD care.

Attention-Deficit/Hyperactivity Disorder

Children's Hospital of Philadelphia303 participantsStarted Mar 2016

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

NCT00311350

This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Postoperative ComplicationsConstipation

Bausch Health Americas, Inc.48 participantsStarted Mar 2006

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

NCT00321581

Background: * AZD2171 is an experimental drug that may slow the growth of cancers by blocking angiogenesis (formation of new blood vessels). * Cancer growth is dependent on angiogenesis for nutrition. * Inhibiting angiogenesis is a new approach to cancer therapy. Objectives: * To determine the side effects of AZD2171 in children and adolescents with cancer. * To determine the highest dose of AZD2171 that can safely be given to children and adolescents with cancer. * To study how the body handles AZD2171. * To determine the effects of AZD2171 on various factors related to angiogenesis. * To determine if AZD2171 can inhibit cancer growth in children and adolescents. Eligibility: -Children and adolescents 2-18 years of age with treatment-resistant solid tumor cancers or acute myelogenous leukemia. Design: * About 40 patients may be included in the study. * AZD2171 is given by mouth in treatment cycles of once a day for 28 days. Treatment may continue unless the cancer worsens or unacceptable side effects develop. * Patients have periodic physical examinations, blood and urine tests and imaging tests (CT, X-rays, MRI) to evaluate disease throughout the course of treatment. Additional blood tests are done to study how the body handles AZD2171, to look for proteins that stimulate angiogenesis, to determine if certain blood vessel cells are affected by AZD2171, and for other research purposes. * Biopsy tissue (when available) is examined for the receptor for new blood vessel formation.

Refractory or Recurrent Solid TumorsAcute Myelogenous Leukemia

National Cancer Institute (NCI)18 participantsStarted May 2006

Philadelphia, Pennsylvania, United States

Communication to Improve Shared Decision-Making in ADHD

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Rheumatoid Arthritis Trials in Other Cities

CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Design of an Affordable Gym for Post Stroke Rehabilitation

Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)

Metformin in Patients With Fragile X

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Multiple Dose Opioid Challenge Study

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

SPRINT - Randomized Trial of Tibial Fracture Fixation

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Other Conditions in Philadelphia